Table 1.
Baseline characteristics of children enrolled at Kibaha and Ujiji
| Variable | Study sites | Overall | |||
|---|---|---|---|---|---|
| Kibaha | Ujiji | ||||
| DP | ASAQ | DP | ASAQ | ||
| Screened | 144 | 101 | 191 | 288 | 724 |
| Enrolled | 88 (61.1) | 69 (68.3) | 88 (46.1) | 88 (30.6) | 333 (46.0) |
| Age in years, mean (SD) | 5.5 (2.8) | 5.0 (2.7) | 4.8 (2.6) | 4.7 (2.8) | 5.0 (2.7) |
| Gender (male), n (%) | 54 (61.4) | 34 (49.3) | 45 (51.1) | 53 (63.2) | 186 (55.7) |
| Weight (kg), median (IQR)** | 17 (13.3–21) | 15 (12.5–22) | 14 (12–18) | 14.6 (11–18.5) | 15 (12–19) |
| Height in cm, median (IQR)*** | 109 (93–123) | 104 (92.5–121) | 101 (83–112) | 101 (86–115) | 104 (90–119) |
| Body temp (°C) ± mean (SD) | 37.9 (1.2) | 37.8 (1.1) | 38.2 (1.3) | 38.0 (1.4) | 38.0 (1.2) |
| Parasitaemia-GMPD (asexual pf/µl) 95% CI* | 24,974 (18,822–33,136) | 24,441 (16,166–36,954) | 36,726 (27,481–49,082) | 36,137 (28,809–45,329) | 30,357 (26,157–35,231) |
°C, degree Celsius; SD, standard deviation; GMPD, Geometric mean parasite density; pf, Plasmodium falciparum; 95% CI, 95% confidence interval; n, number of patients; IQR, Inter quartile range; µl, microlitre; ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response; PP, number of patients involved in the per protocol analysis; LFU, lost to follow-up; WD, withdrawn; n, number of episodes
* p = 0.013, ** p = 0.003, *** p < 0.001